Collaborations

Genetics company signs manufacturing deal for VEGF-2

Published in Gene Therapy Weekly, February 5th, 2004

Corautus Genetics, Inc., (CAQ) has signed a manufacturing agreement with Qiagen NV (QGENF; QIA) and Strathmann Biotech AG to produce VEGF-2 plasmid for anticipated phase III trials and future commercial use.

The company has in inventory the VEGF-2 plasmid required for its upcoming phase IIb clinical trial.

Richard Otto, CEO of Corautus, commented, "Signing this manufacturing agreement is an important building block as we look beyond our phase IIb trial to plan for phase III trials and projected future commercialization of our product. We have decided to enter into this agreement now because it gives us the assurance that if the timelines for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-02-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry